Basking Biosciences, a clinical-stage biopharmaceutical company, was founded to solve the biggest need in acute thrombosis - for a rapid-onset, short-acting thrombolytic drug capable of reopening blocked arteries, and whose activity can be quickly reversed in the event of a bleeding complication. Leveraging RNA aptamer technology, our lead drug candidate, BB-031, targets von Willebrand Factor (vWF), an important structural component of blood clots and driver of the clotting process, and is designed to be safer, more effective, and able to greatly expand the population receiving acute revascularization therapy.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
02/01/24	$55,000,000	Series B	ARCH Venture Partners Insight Partners Longview Ventures Platanus Rev1 Ventures RTW Investments Solas Bioventures The Ohio State University	undisclosed